VRTX and REGN Related Headlines
Go Back- U.S. Biotech stocks: Q1 earnings previews
- Bernstein on US Pharma and Biotech: Who might buy whom?
- RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
- 4Q25/2026 Biotech Earnings Preview: RBC
- Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
